LPCN - Lipocine Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.3900
0.0000 (0.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.3900
Open1.3900
Bid0.00 x 1000
Ask2.25 x 400
Day's Range1.3900 - 1.4600
52 Week Range1.0300 - 3.6300
Volume26,448
Avg. Volume87,439
Market Cap29.835M
Beta (3Y Monthly)-0.10
PE Ratio (TTM)N/A
EPS (TTM)-0.65
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.63
Trade prices are not sourced from all markets
  • Zacks Small Cap Research14 days ago

    LPCN: Tlando Readouts Coming Soon; NDA to Follow

    By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 3Q:18 Operational and Financial Results Lipocine (NASDAQ:LPCN) filed its 3Q:18 10-Q and posted its earnings release on November ...

  • Lipocine Inc (NASDAQ:LPCN): Are Analysts Optimistic?
    Simply Wall St.18 days ago

    Lipocine Inc (NASDAQ:LPCN): Are Analysts Optimistic?

    Lipocine Inc’s (NASDAQ:LPCN): Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men’s and women’s health. The US$30m market-cap company’s loss lessens Read More...

  • GlobeNewswire21 days ago

    Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Associated Presslast month

    Lipocine: 3Q Earnings Snapshot

    The Salt Lake City-based company said it had a loss of 12 cents per share. The company's shares closed at $1.50. A year ago, they were trading at $3.60. _____ This story was generated by Automated Insights ...

  • PR Newswirelast month

    Lipocine Announces Financial and Operational Results for the Three and Nine Months Ended September 30, 2018

    SALT LAKE CITY , Nov. 7, 2018 /PRNewswire/ --   Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and nine months ended September 30, 2018 ...

  • PR Newswirelast month

    Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH

    SALT LAKE CITY , Nov. 5, 2018 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the completion of enrollment in the proof-of-concept clinical study with ...

  • PR Newswirelast month

    Lipocine Announces Completion of Enrollment in Ambulatory Blood Pressure Study for TLANDO™

    SALT LAKE CITY, Nov. 1, 2018 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced the completion of enrollment in the ambulatory blood pressure ("ABPM") clinical study for TLANDO™, the Company's oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism.  This study is being conducted to definitively characterize TLANDO's blood pressure increase effect, if any.

  • Zacks Small Cap Researchlast month

    LPCN: Androgen Therapy in NASH: A Comprehensive Approach

    In their August 2018 corporate presentation, Lipocine Inc. (LPCN) announced the pursuit of a new indication in nonalcoholic steatohepatitis (NASH). The compound addressing this indication is designated LPCN 1144 and will be similar to the current Phase 3 candidate TLANDO, which has many characteristics that may contribute to the resolution of NASH. Prior to the announcement, Lipocine examined a library of literature supportive of androgens in the treatment of NASH and also reviewed its own clinical studies for TLANDO which provide evidence of efficacy for the drug on NASH biomarkers.

  • PR Newswire2 months ago

    Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting® 2018

    SALT LAKE CITY , Oct. 11, 2018 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 results as part of the late-breaker ...

  • PR Newswire2 months ago

    Lipocine to Present at the Ladenburg Thalmann 2018 Healthcare Conference

    SALT LAKE CITY , Sept. 25, 2018 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel , Chairman, President and CEO, will provide a corporate ...

  • Do Institutions Own Shares In Lipocine Inc (NASDAQ:LPCN)?
    Simply Wall St.3 months ago

    Do Institutions Own Shares In Lipocine Inc (NASDAQ:LPCN)?

    The big shareholder groups in Lipocine Inc (NASDAQ:LPCN) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutionsRead More...

  • Zacks Small Cap Research3 months ago

    LPCN: 2Q:18 Operational and Financial Results

    Lipocine (LPCN) filed its 2Q:18 10-Q and posted its earnings release on August 7, 2018 reporting net loss per share of ($0.15). Cash burn for the quarter was ($2.7) million compared to ($4.7) million in 2Q:17.

  • Associated Press4 months ago

    Lipocine: 2Q Earnings Snapshot

    The Salt Lake City-based company said it had a loss of 15 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for ...

  • PR Newswire4 months ago

    Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2018

    SALT LAKE CITY , Aug. 7, 2018 /PRNewswire/ --   Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 2018 . Second ...

  • PR Newswire4 months ago

    Lipocine to Present at the Canaccord Genuity 38th Annual Growth Conference

    SALT LAKE CITY , Aug. 2, 2018 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel , Chairman, President and CEO, will provide a corporate ...

  • ACCESSWIRE6 months ago

    Free Research Reports on Ironwood Pharma and Three More Generic Drugs Stocks

    LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on IRWD sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com observes the recent performance of Horizon Pharma PLC (NASDAQ: HZNP), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Lipocine Inc. (NASDAQ: LPCN), and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN).

  • PR Newswire6 months ago

    Lipocine Announces Dosing in Ambulatory Blood Pressure Study for TLANDO™

    SALT LAKE CITY, June 7, 2018 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced the dosing of the first subject in the ambulatory blood pressure ("ABPM") clinical study for TLANDO™, the Company's oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism.  This study was initiated after receiving FDA feedback on the ABPM clinical study protocol and is being conducted to definitively characterize TLANDO's blood pressure effect, if any.

  • Analysts Expect Breakeven For Lipocine Inc (NASDAQ:LPCN)
    Simply Wall St.7 months ago

    Analysts Expect Breakeven For Lipocine Inc (NASDAQ:LPCN)

    Lipocine Inc’s (NASDAQ:LPCN): Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men’s and women’s health. With the latest financial year lossRead More...

  • Zacks Small Cap Research7 months ago

    LPCN: Another CRL: Updated Timeline Points to 1Q:19 FDA Response

    Lipocine Inc. (LPCN) received a complete response letter (CRL) from the FDA on May 8, 2017 which identified four deficiencies related to the New Drug Application submitted for Tlando, an oral testosterone product for testosterone replacement therapy. Additionally, the company will also schedule a Type A meeting with the FDA in response to the CRL for further guidance on how to proceed.

  • ACCESSWIRE7 months ago

    Free Daily Technical Summary Reports on Horizon Pharma and Three More Generic Drugs Stocks

    LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want a free Stock Review on HZNP sign up now at www.wallstequities.com/registration. WallStEquities.com features the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. The market for generic drugs is based on the premise that patented drugs come with a lifespan of 20 years, which begins from the phase of clinical trials.

  • Benzinga7 months ago

    Lipocine's Regulatory Hiccups Continue: Testosterone Drug Issued Complete Response Letter, Stock Tanks

    Lipocine Inc (NASDAQ: LPCN) stock is poised to lose about one-third of its market value Wednesday, as its Tlando was handed a complete response letter from the FDA for a second time. Lipocine announced Wednesday ahead of the market open the FDA issued a CRL for its new drug application for Tlando, its testosterone replacement therapy intended to treat hypogonadism. A CRL is a communication from the FDA that an application cannot be approved in its present form.

  • Benzinga7 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Walmart Inc (NYSE: WMT ) stock was trading lower by ...

  • PR Newswire7 months ago

    Lipocine Receives Complete Response Letter for TLANDO From U.S. Food and Drug Administration

    SALT LAKE CITY, May 9, 2018 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, announced today that it has received a Complete Response Letter ("CRL") from the United States Food and Drug Administration ("FDA") regarding its New Drug Application ("NDA") for TLANDO™, the Company's oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. A CRL is a communication from the FDA that informs companies that an application cannot be approved in its present form.

  • Benzinga7 months ago

    Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 7) Boston Scientific Corporation (NYSE: BSX ) DexCom, Inc. (NASDAQ: ...